Argireline
Acetyl Hexapeptide-8 (Acetyl Hexapeptide-3)
A synthetic SNAP-25-mimetic hexapeptide developed for topical wrinkle reduction, with mixed small-study human evidence (48.9% anti-wrinkle efficacy in one RCT vs no significant effect in an independent objective-measurement study) and clear delivery limitations for passive skin penetration (PMID 23417317, PMID 38024099, PMID 25786877).
Last updated: 2026-03-10
Safety Summary
Argireline has an excellent safety profile for topical use across all published studies. The original study reported no in vivo oral toxicity and no primary irritation at high doses (PMID 18498523). In the Henseler 2023 split-face study, no significant adverse events, allergic reactions, or skin irritation were reported over 4 weeks (PMID 38024099). In the NIH blepharospasm trial (NCT00942851), 4 subjects (2 active, 2 placebo) experienced minor self-limited eyelid irritation. In the follow-up NIH trial (NCT01750346), one participant in the 0.05% arm experienced puffiness of lower eyelid, and one placebo subject had eyelid tingling. No serious adverse events were attributed to the study drug. Cytotoxicity testing showed anti-proliferative effects only at concentrations 18-10,000 fold higher than doxorubicin, depending on cell type (PMID 24644551). Acute oral LD50 is greater than 2000 mg/kg (PMID 18498523). Notably, a case report documented Mycobacterium abscessus nodules and abscesses after facial argireline injection (not topical use), requiring 5 months of clarithromycin plus moxifloxacin therapy; this represents injection-specific risk, not topical use risk (PMID 33748252). community users have anecdotally reported headaches with high-concentration (10%) use, but this is not documented in clinical literature.
Known Side Effects
uncommon
uncommon
rare
rare
Who Should NOT Use This
Standard cosmetic precaution. Patch test recommended before first use.
No safety data available for use during pregnancy or breastfeeding. Precautionary avoidance recommended.
In the NIH blepharospasm trial, patients with skin conditions resulting in loss of skin integrity were excluded (NCT00942851). Use on damaged skin could increase absorption and irritation risk.
A case report described M. abscessus nodules and abscesses one week after facial argireline injection; the topical literature does not establish injection safety. Argireline is designed for topical use, not injection (PMID 33748252).
Talk to Your Doctor
Before considering Argireline, discuss it with your healthcare provider. Ask about potential interactions with your current medications, whether it is appropriate for your health conditions, and what monitoring may be needed.
Sources: [1-26]
Evidence Assessment
Tier 3 -- Multiple small human studies exist (PMID 18498523: N=10; PMID 23417317: N=60 RCT; PMID 28150423: N=24 RCT; NCT01381484: N=70 RCT but results unpublished; PMID 38024099: N=19 split-face), but results are inconsistent. The strongest positive RCT (PMID 23417317, N=60) showed significant anti-wrinkle efficacy, but the most rigorous independent objective measurement study (PMID 38024099, N=19, Visia camera) found no significant effect. Two NIH Phase 1/2 trials for blepharospasm (NCT00942851 N=24, NCT01750346 N=8) showed no significant benefit. Skin penetration studies call the proposed mechanism into question for topical delivery. No Phase 3 data with published results exists -- the completed Phase 3 trial (NCT01381484) has no posted outcomes. The original rated this Tier 2, which overstates the evidence given the inconsistent results and penetration concerns.
1A synthetic hexapeptide (Argireline) with antiwrinkle activityPMID 18498523
Blanes-Mira C et al. - International Journal of Cosmetic Science (2002) - In vitro + small human pilot - 10 healthy women volunteers (in vivo); chromaffin cell models (in vitro)
10% argireline O/W emulsion reduced wrinkle depth up to 30% after 30 days. In vitro, argireline inhibited neurotransmitter release with potency similar to BoNT A but much lower efficacy. No in vivo oral toxicity (LD50 >2000 mg/kg) or primary irritation at high doses. Mechanism confirmed as SNARE complex destabilization.
Limitations: Only 10 subjects for in vivo portion. Manufacturer-funded (Lipotec). Unusual p-value threshold (p<0.075 cited in some analyses). No blinding described for in vivo portion.
2The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled studyPMID 23417317
Wang Y et al. - American Journal of Clinical Dermatology (2013) - RCT - 60 subjects (3:1 randomization, 45 argireline, 15 placebo)
Subjective evaluation: 48.9% total anti-wrinkle efficacy in argireline group vs 0% in placebo group. Objective evaluation: all roughness parameters significantly decreased in argireline group (p<0.01), no change in placebo (p>0.05).
Limitations: Study was not blinded. 3:1 randomization ratio limits placebo group power. Exact argireline concentration not specified in abstract. Study not replicated. Conducted at single center.
3The anti-wrinkle efficacy of ArgirelinePMID 23464592
Wang Y et al. - Journal of Cosmetic and Laser Therapy (2013) - Animal study - D-galactose-aged mice
Argireline applied twice daily for 6 weeks improved histological structure of skin tissue. Type I collagen fibers increased (p<0.01), type III collagen fibers decreased (p<0.05).
Limitations: Animal model only. Results may not directly translate to human skin.
4The anti wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese SubjectsPMID 23607739
Wang Y et al. - Journal of Cosmetic and Laser Therapy (2013) - RCT + animal study - 60 human subjects + aged mice
In humans, 48.9% anti-wrinkle efficacy with significant wrinkle depth reduction (p<0.01). In aged mice, type I collagen fibers increased (p<0.01) and type III collagen fibers decreased (p<0.05) after 6 weeks.
Limitations: Appears to report overlapping data with PMID 23417317. Animal model used D-galactose aging.
5Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia Complexion Analysis camera systemPMID 38024099
Henseler H - GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW (2023) - Double-blind split-face clinical study - 19 female participants
A hyaluronic-acid serum produced slight, non-significant decreases in wrinkle scores after 4 weeks; the argireline side was not significantly different from the non-argireline side for wrinkle score (p=0.829) or TruSkin Age (p=0.804). No significant adverse events or irritation reported.
Limitations: Small sample. Allowed concomitant cosmetics. Serum contained hyaluronic acids as vehicle. Follow-up lasted only 4 weeks.
6The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3. A prospective, randomized controlled studyPMID 28150423
Raikou V et al. - Journal of Cosmetic Dermatology (2017) - RCT - 24 healthy volunteers, 4 groups (6 per group)
Confirmed antiwrinkle activity of acetyl hexapeptide-3. Significant decrease in TEWL. Combination with tripeptide-10-citrulline showed possible but unclear synergistic mechanism.
Limitations: Very small sample size (6 per group). TEWL finding suggests wrinkle reduction may partly relate to improved hydration rather than neuromuscular effects.
7The study of cellular cytotoxicity of argireline - an anti-aging peptidePMID 24644551
Grosicki M et al. - Acta Biochimica Polonica (2014) - In vitro cytotoxicity - HEK-293 cells, IMR-32 neuroblastoma cells, human primary skin fibroblasts
Dose-dependent anti-proliferative effects observed. IC50 values showed significant cytotoxicity only at concentrations 18 to 10,000 fold higher than doxorubicin reference compound. Confirms argireline is non-cytotoxic at cosmetically relevant concentrations.
Limitations: In vitro study only.
8Argireline: Needle-Free Botox as Analytical ChallengePMID 33482052
Kluczyk A et al. - Chemistry & Biodiversity (2021) - Analytical chemistry - Multiple cosmetic products analyzed
Confirmed presence of argireline and its oxidized form in commercial cosmetic creams and sera via RP-HPLC/MS. Methionine residue identified as oxidation point. Raises quality control concerns about stability.
Limitations: Analytical study, not clinical efficacy study.
9Mycobacterium abscessus infection after facial injection of argireline: A case reportPMID 33748252
Chen et al. - World Journal of Clinical Cases (2021) - Case report - 1 patient
A 45-year-old woman developed erythema, nodules, and abscesses one week after facial argireline injection. M. abscessus cultured. Lesions improved after 5 months of clarithromycin plus moxifloxacin but left scars and pigmentation.
Limitations: Single case. Injectable rather than topical exposure. Does not quantify incidence. Argireline is designed for topical use; injection represents off-label/improper use.
10Public Interest in Acetyl Hexapeptide-8: Longitudinal AnalysisPMID 38376906
Olsson et al. - JMIR Dermatology (2024) - Google Trends longitudinal analysis - Google search volume data 2013-2023
Exponential increase in search volume for 'Argireline' in 2022, likely driven by TikTok. Still searched less than 'Botox.' Confirms growing consumer interest and OTC cosmetic product availability (452 products as of 2020). Notes CIR safety assessments.
Limitations: Ecological study of search trends, not clinical evidence. Cannot assess efficacy.
11Skin scars and wrinkles temporary camouflage in dermatology and oncoesthetics: focus on acetyl hexapeptide-8PMID 33151254
Palmieri B et al. - La Clinica Terapeutica (2020) - Retrospective case series - 26 patients with various skin disorders
10% acetyl hexapeptide-8 gelcream improved skin hydration, elasticity, and sebum parameters. No allergic reactions documented.
Limitations: Retrospective, no control group. Single center. Small sample size.
12A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of BlepharospasmNCT00942851
Lungu C et al. (NINDS/NIH) - ClinicalTrials.gov (Phase 1/2, Completed) (2010) - RCT (double-blind, placebo-controlled) - 24 patients with blepharospasm (12 active, 12 placebo)
Mean time to JBRS reversion: 3.71 months (SD 1.48) for AH-8 vs 3.03 months (SD 0.23) for placebo -- not statistically significant. 4 of 12 active patients showed substantially prolonged intervals (3.3-7.1 months). No serious adverse events. AH-8 concentration was 0.005%.
Limitations: Underpowered (N=24). Very low AH-8 concentration (0.005%). Large gender imbalance.
13Placebo Controlled Double Blind Study of Acetyl Hexapeptide-8 in Treatment of BlepharospasmNCT01750346
Lungu C et al. (NINDS/NIH) - ClinicalTrials.gov (Phase 2, Terminated) (2015) - RCT (double-blind, placebo-controlled) - 8 enrolled (target was 24; terminated early)
Terminated early due to slow recruitment. Two active concentrations tested: 0.025% and 0.05%. At 2 months, placebo group paradoxically showed lower (better) JBRS scores than active groups.
Limitations: Severely underpowered (only 8 enrolled vs 24 planned). Terminated early. Results not interpretable.
14Argireline in Treatment of Periorbital WrinklesNCT01381484
Varothai S et al. (Mahidol University) - ClinicalTrials.gov (Phase 3, Completed) (2009) - RCT (triple-blind, placebo-controlled) - 70 healthy women (35-45 years)
Completed trial of 10% argireline gel applied to periorbital area twice daily for 3 months. Results not published in a peer-reviewed journal and not posted on ClinicalTrials.gov.
Limitations: Results not available. Cannot assess outcomes.
15Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily SkinNCT02597777
UC Davis - ClinicalTrials.gov (Completed) (2015) - Randomized double-blind controlled trial - Not specified in registry
Completed split-face trial of 10% acetyl hexapeptide-8 lotion in Cetaphil base, twice daily for 4 weeks. Results not posted in the source set.
Limitations: No posted outcomes. Cannot assess results.
16Iontophoretic skin permeation of peptidesPMID 25786877
Krishnan G et al. - Drug Delivery and Translational Research (2014) - In vitro permeation study - Excised human skin samples
Iontophoresis (0.4 mA) increased argireline skin permeation up to 30-fold compared to passive diffusion in excised human skin.
Limitations: In vitro study using excised skin. Does not confirm clinical efficacy.
17Enhanced delivery of hydrophilic peptides in vitro by transdermal microneedle pretreatmentPMID 26579370
Zhang et al. - Acta Pharmaceutica Sinica B (2014) - In vitro porcine skin delivery study - Porcine ear skin diffusion experiments
Passive flux of AHP-3 was 0.014 +/- 0.002 umol/cm*h and increased to 0.44 +/- 0.12 umol/cm*h after microneedle pretreatment, more than 31-fold enhancement.
Limitations: Porcine skin model. Measures delivery, not cosmetic outcome.
18Enhanced Skin Permeation of Anti-wrinkle Peptides via Molecular ModificationPMID 29371611
Lim SH et al. - Scientific Reports (2018) - Human cadaver skin and in vitro neuronal assay - Human cadaver skin permeation experiments + DPSC-neuron assays
Parent argireline showed poor skin permeation relative to modified analogues. Arg2 and Arg3 permeated skin more. Arg3 showed greatest in vitro inhibition of glutamate release.
Limitations: Preclinical. Focused on analogues, not direct wrinkle outcomes. Cadaver skin may not reflect living skin.
19High resolution photopolymer for 3D printing of personalised microneedle for transdermal delivery of anti-wrinkle small peptidePMID 33068646
Lim SH et al. - Journal of Controlled Release (2021) - Drug delivery/engineering study - In vitro, human cadaver skin
3D-printed personalized microneedle patches for AHP-3 delivery. Peptide remained stable throughout fabrication. MN patches penetrated human cadaver skin. Minimal cytotoxicity.
Limitations: Proof of concept. No in vivo clinical efficacy data.
20Geometrical optimisation of a personalised microneedle eye patch for transdermal delivery of anti-wrinkle small peptidePMID 31952064
Lim SH et al. - Biofabrication (2020) - Drug delivery/engineering study - In vitro
Optimal microneedle geometry: 800 mcm height, 100 mcm tip, 800 mcm interspacing. Enhanced transdermal delivery of AHP-3 in vitro.
Limitations: Engineering optimization. No clinical data.
213D-bioengineered model of human skeletal muscle tissue with phenotypic features of aging for drug testing purposesPMID 34284359
Mestre R et al. - Biofabrication (2021) - In vitro (3D tissue model) - 3D bioengineered human skeletal muscle tissue
Argireline Amplified demonstrated muscle relaxation effects in the 3D bioengineered tissue model.
Limitations: 3D tissue model, not human clinical data.
22Protective and Anti-Aging Effects of 5 Cosmeceutical Peptide Mixtures on Hydrogen Peroxide-Induced Premature Senescence in Human Skin FibroblastsPMID 33849044
Wu Y et al. - Skin Pharmacology and Physiology (2021) - In vitro - Human skin fibroblasts
Optimal AHP-3 concentration for catecholamine content activity: 400 mcg/mL. Peptide mixture (carnosine + acetyl tetrapeptide-5 + hexapeptide-11 + AHP-3) reduced MDA and hydroxyl free radicals, increased HYP and elastin, boosted SOD and GPx activity.
Limitations: In vitro. Multiple active ingredients make argireline's individual contribution difficult to isolate.
23Influence of the modification of the cosmetic peptide Argireline on the affinity toward copper(II) ionsPMID 37752675
Wyrzykowski D et al. - Journal of Peptide Science (2024) - In vitro (biochemistry/cytotoxicity) - Human skin cells; potentiometric titration, ITC, DFT calculations
Confirmed argireline's affinity for Cu(II) ions. New derivatives characterized. Cytotoxicity assessed in human skin cells.
Limitations: Chemistry study. Clinical relevance of Cu(II) chelation unknown.
24Preparation and stability of cosmetic formulations with an anti-aging peptidePMID 17520155
Ruiz MA et al. - Journal of Cosmetic Science (2007) - Formulation study - N/A (laboratory study)
Prepared and evaluated O/W emulsion and gel formulations. Confirmed acceptable stability.
Limitations: Formulation study, not clinical efficacy trial.
25Facial rejuvenation: combining cosmeceuticals with cosmetic proceduresPMID 25279473
Wisniewski JD et al. - Cutis (2014) - Review - N/A
Review noted AHP-3 as effective topical wrinkle agent; can be used as adjunct to BoNT, potentially reducing injections needed.
Limitations: Narrative review, not primary research.
26Cosmetic potential of Ganoderma lucidum (Reishi) extract in a topical cream formulationPMID 41657122
Dikmen Kucuk S et al. - International Journal of Cosmetic Science (2026) - Comparative in vitro study - HaCaT keratinocytes
Argireline exhibited cytotoxicity at lower concentrations than Reishi extract in HaCaT cells.
Limitations: In vitro comparison study. Argireline was comparator, not primary focus.